U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

The smart money seems to be calling a bottom for the healthcare sector. That could mean it’s time for investors to start taking another look at the industry’s more beleaguered stocks. Since the start ...

Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Pfizer shares have gained ground since a report over the weekend said that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes. Monitor ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio ...

Yum! Brands released its annual Global Citizenship & Sustainability Report, detailing its advancements in reducing carbon emissions, improving packaging and removing barriers. The Company has a ...

The IR spectroscopy market is thriving, fueled by its critical role in real-time monitoring, AI-enhanced data analysis, and ...

up from the restated USD 8.4 billion in the previous quarter This quarterly report examines open-end funds and ETFs focused on impact, sustainability, or environmental, social, and governance (ESG ...